In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Therap, with a price target of $9.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Lineage Cell Therapeutics’ strategic advancements and promising collaborations. The company has entered into a significant partnership with William Demant Invest A/S to accelerate its hearing loss program, ReSonance, which is a cell therapy for auditory neuronal cell transplant. This collaboration is expected to provide up to $12 million in funding, enhancing Lineage’s capabilities in preclinical development and potentially leading to a major partnership with a pharmaceutical giant in the future.
Additionally, Lineage’s OpRegen program, in collaboration with Roche, has shown promising results in its Phase 1/2a trials for geographic atrophy in dry-AMD patients. The data indicates significant differentiation from current treatments, which only slow disease progression. This, coupled with potential funding from a CIRM grant and development milestones from Roche, strengthens Lineage’s financial and strategic position, supporting Pantginis’s Buy rating.
According to TipRanks, Pantginis is an analyst with an average return of -7.9% and a 39.80% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Viking Therapeutics.